Mode
Text Size
Log in / Sign up
N/A N=1,459

Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence

Priapism · Anemia, Sickle Cell

Enrolled (actual)
1,459
Serious AEs
0.0%
Results posted
Aug 2009
Primary outcome: Primary: Enumeration of the Prevalence of Priapism in Males With Sickle Cell Anemia and Sickle Beta Zero Thalassemia. — 18; 58; 160; 189 participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Pediatric, Adult, Older Adult · 5+ yrs
Sex
Male
Sponsor
University of Texas Southwestern Medical Center
Primary completion
Mar 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Enumeration of the Prevalence of Priapism in Males With Sickle Cell Anemia and Sickle Beta Zero Thalassemia.
18; 58; 160; 189; 60
SECONDARY
Characterization of Priapism in Males With Sickle Cell Anemia With Reference to Time of Onset, Duration of Events, Frequency of Episodes, Precipitating or Associated Activities, Treatment Modalities Used, and Outcome of Treatments
SECONDARY
Descriptive Comparison of the Prevalence of Priapism in Males With Sickle Cell Anemia to That Described in Older Patients With Other Sickle Hemoglobinopathies
SECONDARY
Assessment of General Patient and Parent Understanding of Priapism as a Complication of Sickle Cell Disease Gained From Completion of Protocol

Summary

Priapism, a prolonged erection of the penis, is a medical issue that often affects men with sickle cell disease. The purpose of this study is to collect demographic and clinical information on priapism by interviewing men with sickle cell disease.

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of sickle cell anemia or sickle beta zero thalassemia, if 5 years of age or over OR
  • Diagnosis of sickle beta plus thalassemia or sickle hemoglobin C disease, if 15 years of age or over
  • Participant and/or parent or guardian must be able to communicate adequately with the interviewer
  • May participate if currently taking hydroxyurea, undergoing chronic transfusion, or participating in other research studies, including those involving treatments such as arginine, if all other inclusion criteria are met

Exclusion Criteria

Subjects who meet any of the following criteria are disqualified from enrollment in the study:

  • Patient or parent/guardian declines participation.
  • Female.
  • Subject or parent/guardian unable to communicate adequately with the interviewer.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00300235). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search